Federal Circuit Affirms Invalidity of Entecavir Patent As Obvious

We discussed the Bristol-Myers Squibb Co. v. Teva Pharmaceuticals, Inc. in a previous post, in which a Judge Burke of the District of Delaware found the patent for the hepatitis B drug entecavir (the active ingredient in Baraclude) obvious. Last...
By: Carlson Caspers